Raymond James analyst Andrew Cooper downgraded Veracyte to Market Perform from Outperform without a price target. The stock now reflects one of the higher multiples in the space, and while mid-teens consensus revenue growth in 2023 and 2024 should not be made light of, but also don’t necessarily suggest a major upwards shift in the multiple is likely, Cooper tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VCYT:
